Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast01
NL-OMON52270Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started Mar 2022; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON52270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52270.